Earnings Call Summary | Gamida Cell(GMDA.US) Q4 2023 Earnings Conference
Earnings Call Summary | Gamida Cell(GMDA.US) Q4 2023 Earnings Conference
The following is a summary of the Gamida Cell Ltd. (GMDA) Q4 2023 Earnings Call Transcript:
以下是金美達電池有限公司（GMDA）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Gamida Cell reported its first year as a revenue-generating company in 2023, with net revenue of $1.1 million in Q4 2023 and a full-year net revenue of $1.8 million.
Full-year Cost of sales was $1.5 million, resulting in 18.5% gross margin.
R&D expenses decreased to $24.3 million in 2023 from $42.7 million in 2022 due to the company's transition into a commercial stage.
The net loss for 2023 was $63 million, a decrease from 2022's loss of $79.4 million.
Gamida Cell在2023年報告了其作爲創收公司的第一年，2023年第四季度淨收入爲110萬美元，全年淨收入爲180萬美元。
全年銷售成本爲150萬美元，毛利率爲18.5％。
由於公司過渡到商業階段，研發費用從2022年的4,270萬美元降至2023年的2430萬美元。
2023年的淨虧損爲6,300萬美元，較2022年的7,940萬美元虧損有所減少。
Business Progress:
業務進展：
Gamida Cell initiated strategic restructuring, converting $75 million of existing unsecured convertible senior note into equity with Highbridge Capital Management, which will own 100% of the outstanding equity in the newly reorganized company.
This move reduces Gamida Cell's debt by $75 million and trims the annual interest expense by $4.4 million.
The company plans to continue the commercialization of OMISIRGE and extend its relationships with transplant center partners to increase access to the drug.
Gamida Cell啓動了戰略重組，將現有的7500萬美元無抵押可轉換優先票據轉換爲Highbridge Capital Management的股權，後者將擁有這家新重組公司100％的已發行股權。
此舉使Gamida Cell的債務減少了7500萬美元，並將年度利息支出削減了440萬美元。
該公司計劃繼續將OMISIRGE商業化，並擴大與移植中心合作伙伴的關係，以增加獲得該藥物的機會。
More details: Gamida Cell IR
更多詳情： Gamida Cell IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。